Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering AG Sales BENEFIT From Betaseron Study

This article was originally published in The Pink Sheet Daily

Executive Summary

Sales of the multiple sclerosis drug Betaseron and the oral contraceptive Yasmin grew double digits in the first nine months of the year.

You may also be interested in...



Bayer Global R&D Realignment Will Consolidate Research Into Three Sites

Following the acquisition of Schering AG, the move will result in the elimination of 600 positions in the U.S. and $210 mil. in annual savings.

Berlex’ Betaseron Will Compete With Biogen Idec’s Avonex In Early MS

sNDA approval makes interferon beta-1b the second biologic approved for early stage MS treatment.

Berlex’ Yaz Gains Indication For Premenstrual Dysphoric Disorder

The oral contraceptive is the first approved for the treatment of emotional and physical symptoms of PMDD.

Related Content

Topics

UsernamePublicRestriction

Register

PS063432

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel